AMS 8-K SEC Filing Analysis

Latest settled — T+5d

AMS ▼ -14.56% at T+5d

SHORT call ✓ call won +14.56% · α vs SPY +13.84% · entry $1.58 → $1.35

Next anchor: T+20d in 2d

Currently $1.50 · +5.06% from $1.58 entry (call sign-flipped)

Entry anchored
May 14, 09:40 AM ET
via Databento tick

T+1d

-6.96%

call +6.96% · α +5.74%

$1.47

settled 26d ago

T+5d

-14.56%

call +14.56% · α +13.84%

$1.35

settled 20d ago

T+20d

—

call — · α —

—

in 2d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

AMS reported Q1 2026 revenue of $7.1M (+15.9% YoY), beating the $6.9M consensus, but EPS of -$0.09 was a significant miss vs the -$0.01 consensus. Gross margins improved to 18.2% from 15.4% and Adjusted EBITDA rose 18.4% to $1.1M, though the company remains unprofitable with a net loss of -$0.6M. The revenue beat is overshadowed by the large EPS miss and ongoing covenant discussions with its lender.

Key Financial Metrics

Gross Margin

18.2%

Actionable Insight

The large EPS miss and ongoing lender covenant discussions are the dominant signals. Monitor the Q2 2026 earnings for evidence that volume growth translates to profitability and for any resolution of the debt covenant situation.

Key Facts

Revenue of $7.1M beat consensus of $6.9M and grew 15.9% YoY
EPS of -$0.09 missed consensus of -$0.01 by 800%
Gross margin improved to 18.2% from 15.4% YoY
Adjusted EBITDA increased 18.4% to $1.1M from $0.9M
Net loss attributable to AMS was -$0.6M, unchanged from prior year
Direct patient services revenue grew 30.2% to $4.1M
Cash improved to $5.2M from $3.7M at year-end 2025
Company continues discussions with lender regarding debt covenant waivers
Current portion of long-term debt was $16.8M

Financial Impact

EPS miss of -$0.08 vs consensus on a $11M market cap is material; revenue beat of ~$0.2M is modest

epsrevenuegross marginadjusted ebitda

Risk Factors

Debt covenant non-compliance could trigger acceleration or restructuring
Continued operating losses despite revenue growth
High leverage with $16.8M current debt vs $5.2M cash

Market Snapshot

Exchange

NYSE

Sector

Services-Medical Laboratories

Analyst Consensus

80% bullish (5 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001437749-26-016933
Document: asha20260513_8k.htm	0001437749-26-016933
Document: 0001437749-26-016933-index-headers.html	0001437749-26-016933
Document: 0001437749-26-016933-index.html	0001437749-26-016933
Document: 0001437749-26-016933.txt	0001437749-26-016933
8-K Data (Synthetic)	0001437749-26-016933

8 reports for AMS

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+5▲ +8.28%Mar 31, 2026

Filters

Reports for AMS — sortable, filterable
	Type				Now
May 14, 2026 26d ago	8-K BEARISH ★ 6/10	$1.58 $1.35	▲ +14.56%	▲ +13.84%	$1.50 (+5.06%)
May 14, 2026 26d ago	Press Release MIXED ★ 6/10	$1.58 $1.35	▼ −14.56%	▼ −13.84%	$1.50 (−5.06%)
May 7, 2026 4w ago	DEFA14A NEUTRAL ★ 2/10	$2.01 $1.68	▼ −16.42%	▼ −17.92%	$1.50 (−25.37%)
Apr 30, 2026 5w ago	DEFA14A NEUTRAL ★ 3/10	$1.45 $1.81	▲ +24.83%	▲ +23.10%	$1.50 (+3.45%)
Apr 24, 2026 6w ago	8-K BEARISH ★ 6/10	$1.32 $1.84	▼ −39.39%	▼ −38.99%	$1.50 (−13.64%)
Mar 31, 2026 10w ago	8-K BEARISH ★ 8/10	$1.45 $1.33	▲ +8.28%	▲ +12.22%	$1.50 (−3.45%)
Mar 31, 2026 10w ago	Press Release BEARISH ★ 7/10	$1.45 $1.33	▲ +8.28%	▲ +12.22%	$1.50 (−3.45%)
Mar 24, 2026 11w ago	Press Release NEUTRAL ★ 3/10	$1.90 $1.45	▼ −23.68%	▼ −23.26%	$1.50 (−21.05%)

US Market Status

Market Closed — Opens Thu (9h 35m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access